ras homolog family member T2Genealiases: ARHT2 · C16orf39 · MIRO-2 · MIRO2 · RASL
Q-omics provides the consensus-scored RHOT2 profile across patient tissues and cancer cell-line models. RHOT2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RHOT2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RHOT2 protein abundance shows 20,295 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight HNSC, and UCEC as cancer lineages where RHOT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHOT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHOT2 survival associations across molecular data types. RHOT2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHOT2 RNA expression–survival associations across cancer types. High RHOT2 expression shows unfavorable associations in ACC, LIHC, KIRC, SKCM and UVM, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify HNSC as the clearest survival context for RHOT2 RNA expression.
This table summarizes RHOT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RHOT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHOT2 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, KIRP and STAD. The HNSC box plot shows higher RHOT2 RNA expression in tumor versus normal tissue (log2 FC = +0.665, t-test p < 0.001).
This table shows molecular features associated with RHOT2 in patient tissues and cancer cell lines. In patient samples, RHOT2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, RHOT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
